Insulet Corporation · NASDAQ:PODD
Insulet — Raymond James Conference 2023
15 slides from Insulet's conference presentation, Mar 7, 2023
Slide 1: Insulet Corporation – Raymond James Conference
Insulet Corporation Raymond James Conference March 7, 2023 Christian D Podder since 2020 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Today's Agenda
Today’s Agenda 1 Capturing the Large and Underpenetrated Market 2 Realizing the Omnipod 5 Opportunity 3 Penetrating and Leading in the Type 2 Diabetes Market 4 Powering Mission with Strong Financial Profile Giuliana P Podder since 2016 3
Slide 4: Our Mission and How We Achieve It
Our Mission and How We Achieve It Simplify life for people with diabetes • Omnipod platform • Reduce burden • Improve outcomes Market-leading technology Market-leading revenue growth Competitive Advantages Long-term value creation • Talent • Innovation • Scalable Operations • Data infrastructure Jad
Slide 5: Massive Market Opportunity
Massive Market Opportunity Current Total Addressable Market 537M+ ~11M People 2 People with Diabetes Worldwide1 ~64M ~45% ~55% Requiring Insulin Worldwide1 Type 1 Insulin-Intensive Type 2 2024 ~14M With U.S. Basal-Only Pod Morgan M Podder since 2009 1. Source: IDF Atlas 10th Edition. 2. Comprised of
Slide 6: Omnipod Is Unlocking the Largest Market Opportunity
Omnipod Is Unlocking the Largest Market Opportunity Conventional Insulin Pump Multiple Daily Injections (MDI) ~5% ~95% of the global market opportunity1 of the global market opportunity1 Alecia B Podder since 2017 vs. vs. One Pod replaces approximately 14 injections 6 1. Percentage of global insulin
Slide 7: Omnipod 5 Wins on All Dimensions
Omnipod 5 Wins on All Dimensions The Obvious OMNIPOD PLATFORM + OMNIPOD 5 WITH AID = Choice • No needles or tubes • Novel algorithm using micro-dose technology • Discreet, wearable, disposable • Industry-leading time in range • Pay-as-you-go economics for customers and payors • Very few hypoglycemic
Slide 8: Building a Full Range of Options for Type 2
Building a Full Range of Options for Type 2 Patient Journey Diet & Exercise Oral Medications Basal Insulins Basal-Bolus Insulins Omnipod DASH Improved glycemic management and reduction in insulin usage Basal-Only Pod No needles, ease of Omnipod 5 adoption and expected All the benefits of improved ad
Slide 9: Innovation Drives Horizons of Growth
Innovation Drives Horizons of Growth Value 537M+ People with Diabetes Worldwide1 Lead the Industry with ~64M Requiring Insulin Novel Innovations Worldwide1 Expand TAM • Next-generation algorithms Drive Omnipod 5 Growth • Next-generation hardware • AI / machine learning-based data • Basal-Only Pod an
Slide 10: Strong Financial Profile Powering the Mission
Strong Financial Profile Powering the Mission Maximizing Investing Expanding Revenue for Growth Operating Margins ~23% ~19% +~11pts Revenue CAGR R&D Expense CAGR Adjusted Operating Margin 2017 - 20221 2017 - 20221 2017 - 20222 1. CAGR based on reported results. 10 2. Adjusted operating margin for 20
Slide 11: Positioned for Continued Success
Positioned for Continued Success 1 Capturing the Large and Underpenetrated Market 2 Realizing the Omnipod 5 Opportunity 3 Penetrating and Leading in the Type 2 Diabetes Market 4 Powering Mission with Strong Financial Profile Ernesto M Podder since 2017 11
Slide 12: Thank You
Thank You Grant H Podder since 2022 12
Slide 13: Appendix
Appendix Insulet
Slide 14: Reconciliation of Non-GAAP Measures: Revenue
Reconciliation of Non-GAAP Measures Revenue Year Ended December 31, 2022 2021 Percent Change Currency Impact Constant Currency U.S. Omnipod $884.8 651.5 35.8% -% 35.8% International Omnipod 363.0 359.9 0.9% (11.2)% 12.1% Total Omnipod 1,247.8 1,011.4 23.4% (4.0)% 27.4% Drug Delivery 57.5 87.4 (34.2)
Slide 15: Reconciliation of Non-GAAP Measures: Operating Margin
Reconciliation of Non-GAAP Measures Operating Margin Year Ended December 31, 2022 (dollars in millions) Operating Income Revenue Percent of Revenue GAAP $37.6 $1,305.3 2.9% Voluntary Medical Device Corrections 57.9 Legal costs2 25.2 CEO transition costs3 3.4 Non-GAAP $124.1 $1,305.3 9.5% The Company